Charles J. Homcy
CIK: 0001192591
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (24 total)
- Jun 22, 2026BBIO
BridgeBio Pharma, Inc.
Award(A)Direct4K shares- - Jun 20, 2026BBIO
BridgeBio Pharma, Inc.
Tax Payment(F)Direct788 shares at avg. $66.27$52K - Jun 8, 2026MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
18K shares- - May 4, 2026MAZE
Maze Therapeutics, Inc.
Gift(G)Direct7.4K shares- - Nov 19, 2025MAZE
Maze Therapeutics, Inc.
Other(J)Direct1.5K shares- - Oct 23, 2025MAZE
Maze Therapeutics, Inc.
Gift(G)Direct28.4K shares- - Sep 22, 2025MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
18K shares- - Aug 11, 2025BBIO
BridgeBio Pharma, Inc.
Sale(S)Direct50K shares at avg. $48.00$2.4M - Aug 8, 2025BBIO
BridgeBio Pharma, Inc.
Sale(S)Direct58.3K shares at avg. $46.64$2.7M - Aug 8, 2025BBIO
BridgeBio Pharma, Inc.
Sale(S)Direct191.7K shares at avg. $45.87$8.8M - Jun 27, 2025BBIO
BridgeBio Pharma, Inc.
Gift(G)Direct20K shares- - Jun 20, 2025BBIO
BridgeBio Pharma, Inc.
Award(A)Direct6.6K shares- - Feb 3, 2025MAZE
Maze Therapeutics, Inc.
Conversion(C)Direct8.8K shares- - Feb 3, 2025MAZE
Maze Therapeutics, Inc.
Conversion(C)Direct20.7K shares- - Feb 3, 2025MAZE
Maze Therapeutics, Inc.
Conversion(C)Indirect7.4K shares- - Dec 9, 2024MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
45.6K shares- - Dec 9, 2024MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
80.4K shares- - Dec 9, 2024MAZE
Maze Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
80.4K shares- - Dec 9, 2024MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
5.7K shares- - Dec 9, 2024MAZE
Maze Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
5.7K shares- - Dec 9, 2024MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
46.7K shares- - Dec 9, 2024MAZE
Maze Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
46.7K shares- - Nov 26, 2024MAZE
Maze Therapeutics, Inc.
Conversion(C)IndirectSeries D-1 Preferred Stock
71.6K shares- - Nov 26, 2024MAZE
Maze Therapeutics, Inc.
Conversion(C)Indirect8% Convertible Note due 2026
0 shares at avg. $78961.64-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 22, 2026 |  BBIO BridgeBio Pharma, Inc. | Award(A) | 3,990 | - | $0 | Direct |
| Jun 20, 2026 | BBIO BridgeBio Pharma, Inc. | Tax Payment(F) | 788 | $66.27 | $52,221 | Direct |
| Jun 8, 2026 |  MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 18,000 | - | - | Direct |
| May 4, 2026 | MAZE Maze Therapeutics, Inc. | Gift(G) | 7,422 | - | $0 | Direct |
| Nov 19, 2025 | MAZE Maze Therapeutics, Inc. | Other(J) | 1,489 | - | - | Direct |
| Oct 23, 2025 | MAZE Maze Therapeutics, Inc. | Gift(G) | 28,423 | - | - | Direct |
| Sep 22, 2025 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 18,000 | - | - | Direct |
| Aug 11, 2025 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 50,000 | $48.00 | $2,400,000 | Direct |
| Aug 8, 2025 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 58,338 | $46.64 | $2,720,849 | Direct |
| Aug 8, 2025 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 191,662 | $45.87 | $8,791,593 | Direct |
| Jun 27, 2025 | BBIO BridgeBio Pharma, Inc. | Gift(G) | 20,000 | - | - | Direct |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | Award(A) | 6,589 | - | - | Direct |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | Conversion(C) | 8,807 | - | - | Direct |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | Conversion(C) | 20,717 | - | - | Direct |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | Conversion(C) | 7,422 | - | - | Indirect |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 45,638 | - | - | Direct |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 80,385 | - | - | Direct |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 80,385 | - | - | Direct |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 5,704 | - | - | Direct |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 5,704 | - | - | Direct |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 46,675 | - | - | Direct |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 46,675 | - | - | Direct |
| Nov 26, 2024 | MAZE Maze Therapeutics, Inc. | Conversion(C) Series D-1 Preferred Stock | 71,564 | - | - | Indirect |
| Nov 26, 2024 | MAZE Maze Therapeutics, Inc. | Conversion(C) 8% Convertible Note due 2026 | 0 | $78961.64 | - | Indirect |
1-24 of 24 transactions
About HOMCY CHARLES J
HOMCY CHARLES J (SEC CIK 0001192591) files insider reports with the SEC as Director of BridgeBio Pharma, Inc. (BBIO) and Director of Maze Therapeutics, Inc. (MAZE).
Signal8 holds 12 ownership filings by HOMCY CHARLES J (1 Form 3, 11 Form 4), filed between Jan 30, 2025 and Jun 24, 2026. Those filings report 24 transactions, from Nov 26, 2024 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on HOMCY CHARLES J's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by HOMCY CHARLES J
- Jun 22, 2026: Grant or award of BBIO shares (Form 4, code A).
- Jun 20, 2026: Tax withholding of BBIO shares (Form 4, code F).
- Jun 8, 2026: Grant or award of MAZE derivative securities (Form 4, code A).
- May 4, 2026: Gift of MAZE shares (Form 4, code G).
- Nov 19, 2025: Other transaction of MAZE shares (Form 4, code J).
Other insiders filing for BridgeBio Pharma, Inc. (BBIO)
- Apuli Maricel, Chief Accounting Officer
- Kumar Neil, Chief Executive Officer
- Trimarchi Thomas, President and CFO
- Ellis Andrea, Director
- Cook Jennifer E., Director
- Valantine Hannah, Director